FOR IMMEDIATE RELEASE
Society of Gynecologic Oncology
Foundation for Women’s Cancer
Cell Phone: (618) 795-4824
Office Phone: (312) 676-3911
New Phase III SOLO 2-Data Demonstrated a High Survival Benefit in BRCA-Mutated Ovarian Cancer Patients
National Harbor, MD (March 21, 2017) – New data from a clinical trial presented at the Society of Gynecologic Oncology’s 2017 Annual Meeting on Women’s Cancer last week showed significant clinical benefit with a statistically significant improvement in progression free survival for BRCA-mutated ovarian cancer patients with platinum sensitive relapse.
Richard Penson, MD, co-author and Associate Professor at Harvard Medical School, said the SOLO-2 clinical data were practice changing given the magnitude of benefit, with patients on placebo experiencing recurrence within six months and olaparib extending this to more than two years (Blind Independent Central Review: 30.2 months vs. 5.5 months). Olaparib is the first in class PARP inhibitor. PARP inhibitors are a novel class of drugs that have previously demonstrated benefit for ovarian cancer patients with BRCA mutations.
“The data showed that women carrying a germline BRCA mutation were 75 percent less likely to have progression of disease in the study if they got olaparib in the trial,” he said. Progression free survival reflects the time starting study medication until significant worsening of the disease. The data on overall survival not yet mature.
SOLO 2 reported on a new dosage of olaparib, which means that patients need only take four tablets rather than 16 capsules. The tablets were well tolerated, though caused nausea and fatigue, and are safe, with lower than expected incidence of MDS/AML (Myelodysplastic Syndrome / Acute Myelogenous Leukemia). (2 vs. 4 percent with placebo).
The Society of Gynecologic Oncology (SGO) is a 501(c) (6) national medical specialty organization of physicians and allied health care professionals who are trained in the comprehensive management of women with malignancies of the reproductive tract. Visit the SGO website, to learn more at https://www.sgo.org/.